Fine needle aspirating and cutting is superior to Tru-cut core needle in liver biopsy

BACKGROUND:Liver biopsy is the "gold standard" for evaluating liver disorders,but controversies over the potential risk of complications and patient discomfort still exist.Using a 21G fine needle,we developed a new biopsy procedure,fine needle aspirating and cutting(FNAC).Our procedure obtains enough tissue for pathological examination and meanwhile,reduces the risk of biopsy complications.The present study was to determine the safety and efficiency of 21G FNAC compared with 18G Tru-cut core needle(TCN) in liver tumor biopsies.METHODS:Ninety-four patients with unresectable malignant tumors were included in this study.Patients were divided into 2 groups:18G TCN and 21G FNAC.The total positive rate(TPR) and safety of both groups were compared.RESULTS:TPR was not different between the two groups.Liver puncture track subcapsular hemorrhage and arteriovenous shunt were reported with 18G TCN but not with 21G FNAC.The incidence of pain caused by biopsy was higher for the 18G TCN group compared to the 21G FNAC group(P【0.05).About 82.6% of the patients in the 18G TCN group had a sample length 】0.5 cm,but 52.1% in the 21G FNAC group(P【0.05).More than 50% of patients in both groups had sufficient tissue for immunohistochemical examination.CONCLUSIONS:TPR is not different between the 21G FNAC and 18G TCN biopsy procedures,but the safety of 21G FNAC is superior to that of 18G TCN.Tissues obtained by either of these two procedures are sufficient for a pathological diagnosis.